Â鶹Éç

Capricor Therapeutics recently shared an update of the company’s quarterly financial results and operational highlights, including positive results for the ongoing HOPE study with Duchenne muscular dystrophy (Â鶹Éç) patients. The Phase I/II HOPE study (NCT02485938) is assessing the safety and tolerability of investigational…

The American Heart Association (AHA) has awarded its distinguished Scientist Development Grant to a University at Albany researcher for the development of new therapies to treat Duchenne muscular dystrophy (Â鶹Éç). Bijan K. Dey, PhD, is a faculty researcher at the university’s RNA Institute and is working on a class of…

Cardiff University scientists, partnering with the biotech company PerkinElmer, have developed a diagnostic kit to screen for Duchenne muscular dystrophy (Â鶹Éç) in newborns using dried blood spots, according to researchers. The study, “Characterization of a Blood Spot Creatine Kinase Skeletal Muscle Isoform Immunoassay for High-Throughput Newborn Screening of Duchenne…

The investigational therapy MA-0211, also called MTB-1, a potential treatment for Duchenne Muscular Dystrophy (Â鶹Éç), was approved for a Phase I clinical trial, developer Mitobridge announced. The trial will evaluate the therapy’s safety and tolerability and determine its pharmacokinetics and pharmacodynamics profile, or its behavior in the body and mechanism…

The first patient has been dosed in a Phase 2 clinical trial of ACE-083 as a treatment for the muscle impairment in Charcot-Marie-Tooth disease, according to the therapy’s developer, Acceleron Pharma. Acceleron is already evaluating ACE-083 in another Phase 2 trial — this one as a treatment for facioscapulohumeral muscular…

Continuing an 11-year tradition, the Muscular Dystrophy Association (Â鶹Éç) will once again team up with Casey’s General Stores in Iowa to help send children with muscular dystrophy (MD) and related diseases away for a week of fun and friendship to Â鶹Éç Summer Camp at no cost to their families. During…

Jiffy Lube and the Muscular Dystrophy Association (Â鶹Éç) are teaming up again this summer for the 6th annual MUSCLE UP! campaign. Each August for the past five years, Jiffy Lube has campaigned in support of Â鶹Éç-funded muscular dystrophy and related neuromuscular disease research and programs to help…

Researchers at the University of Missouri have developed a new method to efficiently deliver the correct form of dystrophin gene to muscles as a way to correct the faulty gene that characterizes Duchenne muscular dystrophy (Â鶹Éç), a mouse study shows. Their study, “A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic…

The U.S. Food and Drug Administration has approved Capricor Therapeutics’ plan for further development of its CAP-1002 stem cell therapy for Duchenne muscular dystrophy, paving the way for another Phase 2 clinical trial of the treatment this year. The thumbs-up came when Capricor received official minutes from a…

Injecting a smaller but functional form of the dystrophin gene, called microdystrophin, into dogs naturally affected by Duchenne muscular dystrophy allowed them to recover muscle strength and stabilized their overall disease symptoms, a new study shows. “This preclinical study demonstrates the safety and efficacy of microdystrophin, and makes it possible to…